Aktuellt
SENASTE
Redeye retains its positive view of Carasent following a solid Q3 report showing accelerating organic growth and positive EBITDA-CAPEX – to a somewhat higher degree than expected. In addition, we are encouraged by the positive statements about the surgical functionality.
LÄS MER
